Ratings for Biomarin Pharmaceutical BMRN were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 7 | 3 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 3 | 4 | 2 | 0 | 0 |
| 2M Ago | 0 | 2 | 1 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts have recently evaluated Biomarin Pharmaceutical and provided 12-month price targets. The average target is $108.36, accompanied by a high estimate of $120.00 and a low estimate of $86.00. This upward trend is evident, with the current average reflecting a 0.2% increase from the previous average price target of $108.14.
Deciphering Analyst Ratings: An In-Depth Analysis
The analysis of recent analyst actions sheds light on the perception of Biomarin Pharmaceutical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Robyn Karnauskas | Truist Securities | Lowers | Buy | $118.00 | $140.00 |
| Christopher Raymond | Piper Sandler | Maintains | Overweight | $107.00 | $107.00 |
| Paul Matteis | Stifel | Raises | Buy | $115.00 | $112.00 |
| William Pickering | Bernstein | Raises | Outperform | $110.00 | $94.00 |
| Phil Nadeau | TD Cowen | Lowers | Buy | $120.00 | $125.00 |
| George Farmer | Scotiabank | Raises | Sector Perform | $86.00 | $85.00 |
| Paul Matteis | Stifel | Raises | Buy | $112.00 | $108.00 |
| Luca Issi | RBC Capital | Maintains | Sector Perform | $100.00 | $100.00 |
| Gena Wang | Barclays | Lowers | Overweight | $110.00 | $111.00 |
| Cory Kasimov | Evercore ISI Group | Raises | Outperform | $115.00 | $113.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Overweight | $110.00 | $110.00 |
| Whitney Ijem | Canaccord Genuity | Maintains | Hold | $89.00 | $89.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Overweight | $110.00 | $110.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $115.00 | $110.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Biomarin Pharmaceutical. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Biomarin Pharmaceutical compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Biomarin Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Biomarin Pharmaceutical's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Biomarin Pharmaceutical analyst ratings.
Get to Know Biomarin Pharmaceutical Better
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Biomarin Pharmaceutical's Economic Impact: An Analysis
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Biomarin Pharmaceutical's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 19.61%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Biomarin Pharmaceutical's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.05% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Biomarin Pharmaceutical's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.07%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Biomarin Pharmaceutical's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.54%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.21, Biomarin Pharmaceutical adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analyst Ratings: Simplified
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
